Plasma triglyceride concentration was 2-6 (1.2) mmolll in patients with adverse coronary events compared with 2-2 (1.1) mmolIl in those without such events (P < 0.05). Patients with adverse events were younger than those without (54 (9) years v 58 (9) years, P < 0.01). The relative risk of an adverse event in patients with unstable angina and increased plasma triglyceride concentrations was 6-9 compared with those presenting with stable angina and a normal triglyceride concentration (P < 0.02).
(23%) developed one or more adverse events (myocardial infarction five, unstable angina 35 , total coronary occlusion 23) at a median (range) interval of 8 months. Twenty (57%) of the 35 patients with unstable angina developed adverse events compared with 30 (17%) of the 180 with stable angina (P = 0.0001).
Plasma triglyceride concentration was 2-6 (1.2) mmolll in patients with adverse coronary events compared with 2-2 (1.1) mmolIl in those without such events (P < 0.05). Patients with adverse events were younger than those without (54 (9) years v 58 (9) years, P < 0.01). The relative risk of an adverse event in patients with unstable angina and increased plasma triglyceride concentrations was 6-9 compared with those presenting with stable angina and a normal triglyceride concentration (P < 0.02).
Conclusions-The study shows that adverse events are not uncommon in patients awaiting PTCA. Patients at high risk for adverse events may be predicted by the presence of acute coronary syndrome, increased concentration of plasma triglyceride, and younger age at the time of the first angiogram.
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Waiting lists for non-urgent interventional procedures are an integral part of resource allocation in the National Health Service and are based on clinical assessment of relative risk. The British Cardiac Society survey of waiting times in January 1994 showed that significant numbers of patients were on waiting lists for investigation and interventional procedures for more than 12 months. Moreover, the recent council statement on "demand for services and development of a waiting list strategy" highlights the need for identification of those groups of patients who require urgent fast tracking on cardiac waiting lists. The clinical division of patients, however, into a high risk category (requiring urgent intervention) and a low risk (requiring intervention but at a later unspecified date) may not be ideal. Adverse coronary events, usually in association with disease progression, are well recognised in patients awaiting routine coronary intervention procedures. The incidence of, and mechanisms responsible for, coronary stenosis progression and the development of acute coronary events are incompletely understood, but clearly involve interactions between local coronary and systemic factors.' Angiographic stenosis progression is non-linear and largely unpredictable and progression over several years is common.2A Rapid stenosis progression over relatively short periods, however, has also been observed and commonly underlies acute coronary syndrome5-7 and thus may be an important factor in the development of adverse events in patients awaiting coronary intervention. We studied the incidence of, and risk factors associated with, adverse events in such patients. This may help to devise appropriate strategies aimed at minimising adverse events in patients awaiting routine percutaneous transluminal coronary angioplasty (PTCA).
Patients and methods
The patient population consisted of consecutive male patients on a waiting list for routine PTCA between 1 January 1989 and 31 December 1990 after diagnostic angiography. Subclinical stenosis progression is well recognised in clinical practice and it is therefore our practice to repeat coronary angiography using standardised views before the planned procedure in patients who remain on the waiting list for more than 3 months. All surviving patients therefore underwent a second study, either routinely at the time of PTCA Figure 2 shows the event free probability survival curves at the second angiogram for patients presenting with stable angina and those presenting with unstable angina. Unstable angina There is good evidence that major plaque disruption and thrombus formation' 2526 with or without a degree of coronary spasm27 underlies unstable angina. The ideal strategy for dealing with unstable angina that settles with medical therapy is controversial. Dilatation of unstable coronary stenoses with thrombus is associated with increased risk of early and late complications.28-30 Therefore, it is common clinical practice to adopt a policy of "watchful waiting" in patients with unstable angina who settle on conventional medical therapy before proceeding to angioplasty. Our results show that the annual incidence of adverse events in such patients is more than three times greater than in patients presenting with stable angina. This strongly suggests that the potential benefits of a "watchful waiting" policy may have a time limit and this should be weighed against the relatively high risk of rapid stenosis progression in such patients. Recent data presented by Dawkins et al3l indicates that early intervention in patients with unstable angina is associated with a similar event rate as PTCA in stable angina. Whether this can be extrapolated to our patients with medically settled unstable angina remains to be answered. Although the ideal time interval between the acute coronary event and intervention in patients who settle on medical therapy is not known, our findings demonstrate a clear need to monitor such patients closely.
Plasma triglyceride concentration The overall correlation between plasma triglyceride concentration and adverse events was just significant (P = 0 048). The division of patients on the basis of high (2'3 mmol/l) and normal triglyceride concentrations showed a highly significant difference between groups (P = 0003). Thus, patients with increased plasma triglyceride concentrations were at 2-3-fold increased likelihood of an adverse event during follow up irrespective of the clinical presentation. Patients with increased triglyceride concentrations and unstable angina at presentation were more than six times more likely to have an adverse event during follow up compared with those presenting with stable angina and normal triglyceride concentrations. Several large scale epidemiological studies have demonstrated strong univariate and multivariate associations between increased plasma triglyceride concentrations and coronary artery disease.'7 18 32-36 Whether the association between triglyceride and acute events represents a genuine relation, however, is controversial and a number of important angiographic follow up studies have found no such association.3738 Moreover, while some recent lipid lowering studies have reported an association between triglyceride decrease and a reduction in progression39 others have not. 40 The controversy has arisen in part because of the observation in some studies that plasma triglyceride is no longer an independent predictor of coronary artery disease when plasma HDL is included in multiple stepwise analysis. This approach may not be appropriate, however, for such closely interdependent variables as HDL and triglyceride, particularly as triglyceride exhibits greater inter-assay and inter-individual variability.4' Fasting HDL estimation was undertaken in a subgroup of patients in our study and increased plasma triglyceride concentration remained an independent predictor of adverse events when HDL concentrations were included in the regression analysis. These data are consistent with the observations made by the Caerphilly and Speedwell collaborative epidemiological study, in which increased fasting plasma triglyceride was a strong independent risk factor for acute coronary events even after allowance was made for total and HDL cholesterol. 18 As discussed earlier, plaque thrombosis plays a major part in the development of acute coronary events and a strong relation between plasma triglyceride concentration and procoagulant factors has been documented in clinical and laboratory studies. 42 
Conclusions
This study suggests that (1) adverse coronary events are relatively frequent in patients placed on routine waiting lists for PTCA; (2) unstable angina is associated with the development of adverse coronary events even where the patient settles on medical treatment, and (3) the combination of unstable angina at initial presentation and raised fasting plasma triglyceride identifies a subgroup of patients at high risk of adverse events while awaiting coronary intervention.
Our findings have important clinical implications and further larger prospective studies are required to confirm these observations. It remains to be seen whether manipulation of plasma lipids and or earlier intervention in younger patients who present with unstable angina will result in a more favourable outcome.
